ARDM:NSD-Aradigm Corporation (USD)

COMMON STOCK | Other | NSD

Last Closing Price

USD 0.12

Change

0.00 (0.00)%

Market Cap

USD 1.83M

Volume

0.54M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. Its lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq and Lipoquin that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis, cystic fibrosis, and non-tuberculosis mycobacterium. The company is also developing inhaled ciprofloxacin formulations for treatment of patients with cystic fibrosis, and has tested for the prevention and treatment of inhaled bioterrorism infections, such as Coxiella burnetii or Q fever, inhalation anthrax, tularemia, melioidosis and pneumonic plague. Aradigm Corporation has collaboration agreements with Grifols, S.A. The company was founded in 1991 and is headquartered in Hayward, California. On February 15, 2019, Aradigm Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-12-04 )

Largest Industry Peers for Other

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
LGCY Legacy Reserves Inc

N/A

USD61,525,874.67B 1.10 5.30
FTD FTD Companies, Inc

N/A

USD28,725,913.80B N/A N/A
KEYW The KeyW Holding Corporation

N/A

USD24,651,104.38B 166.80 24.48
SNHY Helios Technologies, Inc

N/A

USD17,848,852.22B 1,000,000.00 N/A
QTNA Quantenna Communications, Inc

N/A

USD8,997,243.52B 175.07 79.98
INSY INSYS Therapeutics, Inc

N/A

USD4,995,459.82B 115.90 N/A
CHKE Apex Global Brands Inc

N/A

USD384,202.91B 17.30 N/A
AMCN AirNet Technology Inc

N/A

USD308,457.30B 1.00 N/A
PDVW pdvWireless, Inc

N/A

USD95,944.74B N/A N/A
AIPT Predictive Oncology Inc

N/A

USD38,513.36B N/A N/A

ETFs Containing ARDM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Other)
Market Performance vs. Exchange (OTCQB - U.S. Registered)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -97.65% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -97.65% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -38.90% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.90% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 57.15% N/A N/A N/A N/A
Risk Adjusted Return -68.07% N/A N/A N/A N/A
Market Capitalization 1.83M N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Other)
Ratio vs. Market
(OTCQB - U.S. Registered)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -83.22% N/A N/A N/A N/A
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio -119.77% N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.81 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike